Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1995 Dec 16;311(7020):1583–1584. doi: 10.1136/bmj.311.7020.1583

Selegiline in Parkinson's disease.

D B Calne
PMCID: PMC2551489  PMID: 8555790

Full text

PDF
1583

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allain H., Cougnard J., Neukirch H. C. Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT). Acta Neurol Scand Suppl. 1991;136:73–78. doi: 10.1111/j.1600-0404.1991.tb05024.x. [DOI] [PubMed] [Google Scholar]
  2. Birkmayer W., Knoll J., Riederer P., Youdim M. B., Hars V., Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm. 1985;64(2):113–127. doi: 10.1007/BF01245973. [DOI] [PubMed] [Google Scholar]
  3. Brannan T., Yahr M. D. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol. 1995 Jan;37(1):95–98. doi: 10.1002/ana.410370117. [DOI] [PubMed] [Google Scholar]
  4. Calne D. B. The free radical hypothesis in idiopathic parkinsonism: evidence against it. Ann Neurol. 1992 Dec;32(6):799–803. doi: 10.1002/ana.410320615. [DOI] [PubMed] [Google Scholar]
  5. Elizan T. S., Yahr M. D., Moros D. A., Mendoza M. R., Pang S., Bodian C. A. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients. Arch Neurol. 1989 Dec;46(12):1280–1283. doi: 10.1001/archneur.1989.00520480022013. [DOI] [PubMed] [Google Scholar]
  6. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol. 1992 Dec;32(6):804–812. doi: 10.1002/ana.410320616. [DOI] [PubMed] [Google Scholar]
  7. Myllylä V. V., Sotaniemi K. A., Vuorinen J. A., Heinonen E. H. Selegiline as initial treatment in de novo parkinsonian patients. Neurology. 1992 Feb;42(2):339–343. doi: 10.1212/wnl.42.2.339. [DOI] [PubMed] [Google Scholar]
  8. Schulzer M., Mak E., Calne D. B. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol. 1992 Dec;32(6):795–798. doi: 10.1002/ana.410320614. [DOI] [PubMed] [Google Scholar]
  9. Tetrud J. W., Langston J. W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 1989 Aug 4;245(4917):519–522. doi: 10.1126/science.2502843. [DOI] [PubMed] [Google Scholar]
  10. Ward C. D. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):217–220. doi: 10.1136/jnnp.57.2.217. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES